Role of Strontium Ranelate in Proximal Femur Fragility Fractures.
NCT ID: NCT05712616
Last Updated: 2023-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
100 participants
INTERVENTIONAL
2021-11-01
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
NCT07242612
Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)
NCT00479037
The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA
NCT03133195
RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients
NCT07056478
A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis
NCT00632216
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Strontium group
Trial drug given in the form of sachet 2gm/sachet once every day
Strontium Ranelate
Dual mode of action, anabolic and anti-resorptive
Placebo (Lactose)
Look, smell, taste alike lactose 2gm/sachet in form of sachet
Lacto-N-Hexaose
Placebo look alike drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Strontium Ranelate
Dual mode of action, anabolic and anti-resorptive
Lacto-N-Hexaose
Placebo look alike drug
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ORIF will include hip cannulated screws, dynamic hip screw and intra-medullary nails.
Exclusion Criteria
* Patients with pathological fractures like tumor, osteopetrosis etc.
* Patients with prior Ischemic heart diseases and underwent PCI or CABG
60 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AO Trauma Middle East and North Africa
UNKNOWN
Aga Khan University Hospital, Pakistan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Marij Zahid
Instructor orthopedic surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aga Khan University Hospital
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6189
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.